NO20040987L - Biologiske produkter - Google Patents

Biologiske produkter

Info

Publication number
NO20040987L
NO20040987L NO20040987A NO20040987A NO20040987L NO 20040987 L NO20040987 L NO 20040987L NO 20040987 A NO20040987 A NO 20040987A NO 20040987 A NO20040987 A NO 20040987A NO 20040987 L NO20040987 L NO 20040987L
Authority
NO
Norway
Prior art keywords
disclosed
cdr
antibody
antibody molecules
biological products
Prior art date
Application number
NO20040987A
Other languages
English (en)
Inventor
Andrew George Popplewell
Simon Peter Tickle
Karen Zinkewich-Peotti
Robert Kendall Morrison
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of NO20040987L publication Critical patent/NO20040987L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
NO20040987A 2001-10-10 2004-03-08 Biologiske produkter NO20040987L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124317.9A GB0124317D0 (en) 2001-10-10 2001-10-10 Biological products
PCT/GB2002/004619 WO2003031475A2 (en) 2001-10-10 2002-10-10 Antibodies against kdr, their production and uses

Publications (1)

Publication Number Publication Date
NO20040987L true NO20040987L (no) 2004-05-10

Family

ID=9923562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040987A NO20040987L (no) 2001-10-10 2004-03-08 Biologiske produkter

Country Status (24)

Country Link
US (2) US7452976B2 (no)
EP (1) EP1438340B1 (no)
JP (2) JP4323312B2 (no)
KR (2) KR101018908B1 (no)
CN (1) CN1568331A (no)
AT (1) ATE482234T1 (no)
AU (1) AU2002334135B8 (no)
BR (1) BR0212756A (no)
CA (1) CA2458464A1 (no)
CO (1) CO5580838A2 (no)
DE (1) DE60237778D1 (no)
DK (1) DK1438340T3 (no)
EA (1) EA010970B1 (no)
ES (1) ES2351208T3 (no)
GB (1) GB0124317D0 (no)
HU (1) HUP0401618A3 (no)
IL (1) IL160849A0 (no)
IS (1) IS7173A (no)
MX (1) MXPA04003274A (no)
NO (1) NO20040987L (no)
NZ (1) NZ532758A (no)
PL (1) PL208848B1 (no)
WO (1) WO2003031475A2 (no)
ZA (1) ZA200401910B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
NZ544911A (en) * 2003-07-22 2008-12-24 Schering Ag RG1 antibodies and uses thereof
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP2322622A3 (en) * 2005-03-25 2012-03-07 National Research Council of Canada Method for isolation of soluble polypeptides
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
SI2125894T1 (sl) 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN101883790B (zh) 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
MA33122B1 (fr) * 2009-02-17 2012-03-01 Ucb Pharma Sa Molecules d'anticorps ayant une specificite pour ox40 humain
CN101531718B (zh) * 2009-04-22 2011-11-02 中国人民解放军南京军区军事医学研究所 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
PL2993231T3 (pl) 2009-09-24 2019-01-31 Ucb Biopharma Sprl Szczep bakteryjny do ekspresji rekombinowanego białka mający degp pozbawione aktywności proteazowej przy zachowaniu aktywności białka opiekuńczego i nokauty genów tsp i ptr
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
PT2731973T (pt) 2011-07-13 2018-02-22 Ucb Biopharma Sprl Estirpe hospedeira bacteriana que expressa dsbc recombinante
TWI571473B (zh) 2011-11-02 2017-02-21 埃派斯進有限公司 抗ｋｄｒ抗體及使用方法
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
AU2013222935B2 (en) 2012-02-24 2016-03-10 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
AU2013348570B2 (en) 2012-11-21 2017-01-12 Pharmabcine Inc. Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition comprising same
US11866506B2 (en) 2017-04-21 2024-01-09 Mellitus, Llc Anti-CD59 antibodies
JP2022502079A (ja) * 2018-09-19 2022-01-11 トーシェント，インコーポレーテッド がん関連抗体組成物および使用方法
JP2022514615A (ja) * 2018-12-20 2022-02-14 アルバート アインシュタイン カレッジ オブ メディスン ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
AU3850299A (en) * 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
CA2361553A1 (en) * 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof

Also Published As

Publication number Publication date
CO5580838A2 (es) 2005-11-30
KR20040097983A (ko) 2004-11-18
CA2458464A1 (en) 2003-04-17
JP2005516590A (ja) 2005-06-09
ATE482234T1 (de) 2010-10-15
NZ532758A (en) 2008-04-30
BR0212756A (pt) 2004-11-16
EP1438340B1 (en) 2010-09-22
PL370344A1 (en) 2005-05-16
JP2009108086A (ja) 2009-05-21
US20090269840A1 (en) 2009-10-29
WO2003031475A2 (en) 2003-04-17
PL208848B1 (pl) 2011-06-30
JP4323312B2 (ja) 2009-09-02
DK1438340T3 (da) 2010-11-22
KR101018908B1 (ko) 2011-03-02
EA200400519A1 (ru) 2004-12-30
ES2351208T3 (es) 2011-02-01
HUP0401618A3 (en) 2012-03-28
US20050181448A1 (en) 2005-08-18
KR20070116110A (ko) 2007-12-06
US7452976B2 (en) 2008-11-18
WO2003031475A3 (en) 2004-03-25
WO2003031475A8 (en) 2004-10-14
MXPA04003274A (es) 2004-07-08
EP1438340A2 (en) 2004-07-21
DE60237778D1 (de) 2010-11-04
CN1568331A (zh) 2005-01-19
HUP0401618A2 (hu) 2004-11-29
IL160849A0 (en) 2004-08-31
US7842787B2 (en) 2010-11-30
EA010970B1 (ru) 2008-12-30
GB0124317D0 (en) 2001-11-28
ZA200401910B (en) 2005-03-09
AU2002334135B8 (en) 2009-01-29
IS7173A (is) 2004-03-05
AU2002334135B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
NO20040987L (no) Biologiske produkter
LTPA2017043I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
CY1121173T1 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
WO2002093519A3 (de) Humane hochaffine antikörperfragmente gegen essentielle proteine (ns3) von hepatitis-c-virus
MXPA03000980A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application